Relmada Therapeutics, Inc. RLMD Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions at other companies

Corvex MOVE

4%-0.2pp

Norwood FinancialNWFL

4.1%-0.3pp

Achieve Life SciencesACHV

0%—

BeldenBDC

4%-0.4pp

SyscoSYY

3.7%-0.4pp

The Honest CompanyHNST

$0-100%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions discount for postvesting restrictions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award fair value assumptions discount for postvesting restrictions?: Relmada Therapeutics, Inc. (RLMD) reported share based compensation arrangement by share based payment award fair value assumptions discount for postvesting restrictions of 3.9% in Q1 2026.